Related Experiment Videos
Mutation of cell cycle regulators and their impact on superficial bladder cancer
1Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Abstract:
Early cytogenetic studies in bladder cancer identify regions of chromosomal gain or loss that can be candidate loci for oncogenes and tumor suppressor genes. Oncogenes with potential prognostic significance identified in bladder cancer the RAS family, epidermal growth factor receptor, ERBB-2, MDM2, and cyclin D1. The TP53 gene has been the most thoroughly characterized tumor suppressor gene in bladder cancer, with correlation of TP53 alterations with type of carcinogenic exposure, tumor stage and grade, as well as prognosis. Studies evaluating alterations of the retinoblastoma pathway have identified the retinoblastoma gene, RB, p161NK4A/CDKN2, and E2F-1 as tumor suppressor genes with potential prognostic significance in patients with bladder cancer. Better understanding of the genetic mechanisms underlying bladder tumor development and progression will allow better prevention, diagnosis, and treatment strategies.
Insights
Genetic alterations in bladder cancer, including oncogenes like RAS and tumor suppressor genes such as TP53 and RB, are crucial for understanding tumor development and prognosis. This knowledge aids in developing better prevention and treatment strategies.
Area of Science:
- Oncology
- Cancer Genetics
- Molecular Biology
Background:
- Cytogenetic studies reveal chromosomal abnormalities in bladder cancer.
- These abnormalities indicate potential oncogene and tumor suppressor gene involvement.
- Understanding these genetic changes is key to improving patient outcomes.
Purpose of the Study:
- To identify oncogenes and tumor suppressor genes implicated in bladder cancer development and progression.
- To explore the prognostic significance of specific genetic alterations.
- To correlate genetic findings with clinical parameters like exposure, stage, grade, and prognosis.
Main Methods:
- Review of early cytogenetic studies in bladder cancer.
- Analysis of identified oncogenes (RAS family, EGFR, ERBB-2, MDM2, cyclin D1).
- Characterization of tumor suppressor genes (TP53, RB, p16INK4A/CDKN2, E2F-1) and their alterations.
Main Results:
- Several oncogenes (RAS, EGFR, ERBB-2, MDM2, cyclin D1) show potential prognostic significance.
- TP53 alterations correlate with carcinogenic exposure, tumor stage, grade, and prognosis.
- Tumor suppressor genes in the retinoblastoma pathway (RB, p16INK4A/CDKN2, E2F-1) also have prognostic implications.
Conclusions:
- Genetic mechanisms underlying bladder tumor development are increasingly understood.
- Identification of key oncogenes and tumor suppressor genes offers prognostic value.
- Further research into these genetic alterations will enhance bladder cancer prevention, diagnosis, and treatment.